Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)

Trial Profile

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Tranexamic acid (Primary)
  • Indications Septic shock
  • Focus Therapeutic Use
  • Acronyms SSAIL
  • Sponsors Leading BioSciences
  • Most Recent Events

    • 06 Jun 2016 Status changed from recruiting to discontinued due to inability to enrol participants.
    • 10 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 04 Feb 2015 Planned initiation date changed from 1 Mar 2015 to 1 Jun 2015, as reported in a Leading BioSciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top